Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy

Por Gertz, Morie A., Lacy, Martha Q., Dispenzieri, Angela, Greipp, Philip R., Litzow, Mark R., Henderson, Kimberly J., Van Wier, Scott A., Ahmann, Greg J., Fonseca, Rafael
Publicado em 2005

Multiple myeloma cells’ capacity to decompose H(2)O(2) determines lenalidomide sensitivity

Por Sebastian, Sinto, Zhu, Yuan X., Braggio, Esteban, Shi, Chang-Xin, Panchabhai, Sonali C., Van Wier, Scott A., Ahmann, Greg J., Chesi, Marta, Bergsagel, P. Leif, Stewart, A. Keith, Fonseca, Rafael
Publicado no Blood (2017)

Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasone

Por Kumar, Shaji K., Uno, Hajime, Jacobus, Susanna J., Wier, Scott A. Van, Ahmann, Greg J., Henderson, Kimberly J., Callander, Natalie S., Haug, Jessica L., Siegel, David S., Greipp, Philip R., Fonseca, Rafael, Rajkumar, S. Vincent
Publicado em 2011

Prevalence of BCL-2/J(H) Translocation in Healthy African Americans

Por Colon-Otero, Gerardo, Van Wier, Scott A., Ahmann, Greg J., Braggio, Esteban, Albertie, Monica L., Weis, Jennifer A., Ailawadhi, Sikander, Cerhan, James R., Vishnu, Prakash, Jorgensen, Matthew S., Foran, James M., Thomas, Colleen S., Fonseca, Rafael
Publicado no Ann Hematol (2016)

Clinical implication of centrosome amplification in plasma cell neoplasm

Por Chng, Wee J., Ahmann, Greg J., Henderson, Kim, Santana-Davila, Rafael, Greipp, Philip R., Gertz, Morie A., Lacy, Martha Q., Dispenzieri, Angela, Kumar, Shaji, Rajkumar, S. Vincent, Lust, John A., Kyle, Robert A., Zeldenrust, Steven R., Hayman, Suzanne R., Fonseca, Rafael
Publicado em 2006

A multiple myeloma-specific capture sequencing platform discovers novel translocations and frequent, risk-associated point mutations in IGLL5

Por White, Brian S., Lanc, Irena, O’Neal, Julie, Gupta, Harshath, Fulton, Robert S., Schmidt, Heather, Fronick, Catrina, Belter, Edward A., Fiala, Mark, King, Justin, Ahmann, Greg J., DeRome, Mary, Mardis, Elaine R., Vij, Ravi, DiPersio, John F., Levy, Joan, Auclair, Daniel, Tomasson, Michael H.
Publicado no Blood Cancer J (2018)

“Direct to Drug” screening as a precision medicine tool in multiple myeloma

Por Bonolo de Campos, Cecilia, Meurice, Nathalie, Petit, Joachim L., Polito, Alysia N., Zhu, Yuan Xiao, Wang, Panwen, Bruins, Laura A., Wang, Xuewei, Lopez Armenta, Ilsel D., Darvish, Susie A., Ahmann, Greg J., Henderson, Kimberly J., Tian, Shulan, Kruse, Jonas J., Stewart, William M., Larsen, Jeremy T., Reeder, Craig B., Dingli, David, Kapoor, Prashant, Kumar, Shaji K., Fonseca, Rafael, Bergsagel, P. Leif, Braggio, Esteban, Stewart, A. Keith
Publicado no Blood Cancer J (2020)

IAP antagonists induce anti-tumor immunity in multiple myeloma

Por Chesi, Marta, Mirza, Noweeda N., Garbitt, Victoria M., Sharik, Meaghen E., Dueck, Amylou C., Asmann, Yan W., Akhmetzyanova, Ilseyar, Kosiorek, Heidi E., Calcinotto, Arianna, Riggs, Daniel L., Keane, Niamh, Ahmann, Greg J., Morrison, Kevin M., Fonseca, Rafael, Lacy, Martha Q., Dingli, David, Kumar, Shaji K., Ailawadhi, Sikander, Dispenzieri, Angela, Buadi, Francis, Gertz, Morie A., Reeder, Craig B., Lin, Yi, Chanan-Khan, Asher Alban, Stewart, A. Keith, Fooksman, David, Bergsagel, P. Leif
Publicado no Nat Med (2016)